Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a actinomycin D monotherapy in older or unfit patients with NPM1-wild type acute myeloid leukemia
2017-000282-68Phase 2Terminated
- Sponsor
- University of Perugia
- Start
- Nov 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of actinomycin D in acute myeloid leukemia (AML), sponsored by University of Perugia. Primary endpoint: Complete hematological response rate after two cycles. Started Nov 2020; status: terminated.
02
Drugs
actinomycin D
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2017-000282-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000282-68.